# Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema

> **NCT05324774** · PHASE3 · UNKNOWN · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 346 (estimated)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** 9MW0813
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT05324774
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-28
- **Primary completion:** 2023-09-30
- **Final completion:** 2024-07-30
- **Target enrollment:** 346 (ESTIMATED)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05324774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05324774, "Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05324774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*